Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : QPX9003
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Qpex Biopharma
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Brii Bio will acquire exclusive global rights for the development and commercialization of QPX9003 (BRII-693), a novel synthetic lipopeptide in development for the treatment of MDR/XDR gram-negative bacterial infections, to expand from its existing right...
Product Name : QPX9003
Product Type : Antibiotic
Upfront Cash : $24.0 million
June 25, 2023
Lead Product(s) : QPX9003
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Qpex Biopharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : BRII-297
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BRII-297 is a gamma-aminobutyric acid A receptor positive allosteric modulator and first-of-its-kind long-acting injectable therapeutic candidate in development for the treatment of various anxiety and depressive disorders.
Product Name : BRII-297
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 31, 2023
Lead Product(s) : BRII-297
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Islatravir Prodrug,Rilpivirine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BRII-732/BRII-778 combination is currently in Phase 1 development in the U.S. as therapy for human immunodeficiency virus infection that can be administered on weekly basis potentially preferable choice for patients currently receiving once-daily treatme...
Product Name : BRII-732
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2022
Lead Product(s) : Islatravir Prodrug,Rilpivirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rilpivirine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Brii Biosciences Presents Data on Novel HIV Therapeutics at IDWeek 2022
Details : BRII-778 (rilpivirine), a modified-release Oral Formulation is being evaluated in the early-stage clinical trials studies for the treatment of patients suffering from HIV-infections.
Product Name : BRII-778
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2022
Lead Product(s) : Rilpivirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amubarvimab,Romlusevimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Studies conducted by independent labs demonstrated the BRII-196 (amubarvimab) in combination with romlusevimab retains neutralizing activity against COVID-19 Omicron variant.
Product Name : BRII-196
Product Type : Antibody
Upfront Cash : Inapplicable
September 05, 2022
Lead Product(s) : Amubarvimab,Romlusevimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amubarvimab,Romlusevimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Independent lab results demonstrate that the BRII-196 (amubarvimab/romlusevimab) combination therapy retains neutralizing activity against currently dominant COVID-19 strains, as previously demonstrated with all variants of concern to date.
Product Name : BRII-196
Product Type : Antibody
Upfront Cash : Inapplicable
July 26, 2022
Lead Product(s) : Amubarvimab,Romlusevimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amubarvimab,Romlusevimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : TSB Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BRII-196 (amubarvimab) and romlusevimab are non-competing SARS-CoV-2 mAB derived from convalesced COVID-19 patients, have been specifically engineered to reduce risk of antibody-dependent enhancement and prolong plasma half-lives for potentially more dur...
Product Name : BRII-196
Product Type : Antibody
Upfront Cash : Inapplicable
July 07, 2022
Lead Product(s) : Amubarvimab,Romlusevimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : TSB Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VIR-2218,BRII-179
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The data demonstrate that BRII-835 (VIR-2218), an small interfering ribonucleic acid that mediates RNA interference, results in dose-dependent reduction in hepatitis B surface antigen in Chinese patients with chronic HBV infection who received two doses ...
Product Name : BRII-835
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 31, 2022
Lead Product(s) : VIR-2218,BRII-179
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amubarvimab,Romlusevimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Sinopharm
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership will accelerate stockpiling, channel distribution and regional access of the amubarvimab/romlusevimab combination. Amubarvimab and Romlusevimab are non-competing SARS-CoV-2 monoclonal neutralizing antibodies derived from convalesced COVID...
Product Name : BRII-196
Product Type : Antibody
Upfront Cash : Undisclosed
March 30, 2022
Lead Product(s) : Amubarvimab,Romlusevimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Sinopharm
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Amubarvimab,BRII-198
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BRII-196 and BRII-198 are non-competing SARS-CoV-2 monoclonal neutralizing antibodies derived from convalesced COVID-19 patients. Their non-overlapping epitope binding regions provide a high degree of neutralization activity against SARS-CoV-2.
Product Name : BRII-196
Product Type : Antibody
Upfront Cash : Inapplicable
September 10, 2021
Lead Product(s) : Amubarvimab,BRII-198
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable